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Fig. 1 A 54-year old woman with newly diagnosed EBV-positive
classical Hodgkin’s lymphoma was referred for initial staging with
18F-FDG PET/CT. The 18F-FDG PET/CT scan revealed a conglom-
erate of multiple hypermetabolic cervical nodal manifestations on the
left side (level II–V, Deauville score 5, SUVmax 40.7), corresponding
to a stage II disease, as shown on the maximum intensity projection
image (A; blue arrow). In addition, multifocal intense 18F-FDG uptake
in the right breast (SUVmax 14.4) and hypermetabolic axillary lymph
nodes on the right side (SUVmax 11.3) — highly suspicious for a
second primary malignancy — were detected (A; green arrows).
Consecutive fine-needle aspiration cytology of all lesions confirmed
the simultaneous diagnosis of multifocal breast cancer (G2, HER2-
positive) with axillary metastases on the right side. Moreover, the
initial 18F-FDG PET/CT scan revealed two focal lesions in the right
thyroid lobe (SUVmax 11.0; A–D; red arrows). Given the confirmed
diagnosis of two tumor entities and the lack of a therapeutic con-
sequence, initial histopathological examination of the two thyroidal
lesions was not performed. After three cycles of neoadjuvant che-
motherapy (3 × 5-fluorouracil, epirubicin, and cyclophosphamide
(FEC); 3 × docetaxel, trastuzumab, and pertuzumab) and additional
radiation therapy to the neck, the patient received a follow-up 18F-FDG
PET/CT scan that revealed a complete response both of the Hodgkin’s
lymphoma (according to Lugano 2014 criteria) and the metastasized
breast cancer (in terms of RECIST and PERCIST) with concomitant
reactive activation of the bone marrow and of the spleen (H). Inter-
estingly, the two previously hypermetabolic thyroid lesions also
showed a complete response (E–G) — ultimately indicating a
malignant origin, e.g., Hodgkin’s lymphoma of the thyroid, breast
cancer metastases to the thyroid gland or a third primary thyroid
tumor. While the incidental finding of a focal thyroid 18F-FDG uptake
in 18F-FDG PET/CT is rare and only occurs at a frequency of
1.1–4.2% [1], thyroid incidentalomas carry a significant risk of
malignancy that is reported to be 23.0–63.6% [1]. This risk of
malignancy is especially high when thyroid lesions show focal 18F-
FDG uptake [2, 3], i.e., when the PET scan (rather than the CT image)
shows a suspicious finding and when their SUVmax is above 4.2 [2].
Histopathological evaluation of thyroid incidentalomas shows papil-
lary thyroid carcinoma to be the most prevalent thyroid malignancy,
whereas metastases to the thyroid gland are mostly derived from renal
cell carcinoma (in a clinical setting) or lung cancer (in autopsy series).
Hodgkin’s lymphoma of the thyroid shows a female preponderance,
but is extremely rare, and breast cancer metastases to the thyroid are
seldomly reported. However, an association between thyroid cancer
and breast cancer has been described in the literature. For the eva-
luation of a thyroid incidentaloma, both PET (focal 18F-FDG uptake,
high SUVmax) and CT (low attenuation) can be helpful [2] while
ultrasound is still the mainstay to stratify the risk of malignancy. Still,
prompt histopathological examination should be performed for defi-
nitive diagnosis. Here, a biopsy of the thyroid incidentalomas would
have been obligatory in case of persistence or progression under
treatment
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